|
|
|
|
|
HONG KONG, Apr 11, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. ("Essex Medipharma"), has entered into an Agency Agreement ("Agency Agreement") with Gunze Medical Devices (Shenzhen) Ltd. ("Gunze Shenzhen"), a wholly-owned subsidiary of Gunze Limited ("Gunze") in Japan, for PELNAC Absorbable Dressing ("PELNAC"), for a product manufactured by Gunze. Pursuant to the Agency Agreement, Essex Medipharma will be the exclusive agent of PELNAC in Mainland China for a period of 5 years, starting from 2023 to 2027.
PELNAC, the world's leading artificial dermis product, consists of a collagen sponge layer, which provides a scaffold for cellular invasion and capillary growth, and a silicone film layer, which is reinforced with non-adhesive gauze. It is suitable for full skin defects: (1) Full-thickness burns, (2) Traumatic skin defect wounds, (3) Skin defects after tumor or nevus removal, (4) Sites of skin flap extraction. PELNAC is not only available in Mainland China and Japan, but has also obtained the CE marking in the EU and FDA approval in the US.
PELNAC works well with Essex's bFGF-formulated products, the combination of the two products has a synergistic effect that would accelerate the vascularization and improve the viability rate in wound repair and healing.
The Group believes that with its strong marketing system and extensive distribution network, this cooperation will accelerate the market expansion of PELNAC in Mainland China and will further strengthen the Group's development in the field of wound healing for the clinical needs of more patients.
About Gunze Shenzhen
Gunze Medical Devices (Shenzhen) Limited was established in 2010 as a wholly owned subsidiary of Gunze Limited in China, focusing on the development, production and sales of regenerative medicine, and is responsible for the registration, marketing and after-sales management of Gunze Limited's absorbable medical materials in China. Its main products include absorbable dressing, PLLA bioabsorbable bone fixation devices, absorbable reinforcement felt and absorbable artificial dura mater, which are widely used in various departments such as thoracic surgery, orthopedics, burn surgery and neurosurgery.
About Essex
Essex Bio-Technology Limited is a biopharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic b-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and Shilishun (Iodized Lecithin Capsules) etc.. The products of the Company are principally prescribed for the treatment of wound healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 10,900 hospitals and managed directly by its 43 regional sales offices in China. Leveraging its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.
Media Enquiry:
Strategic Financial Relations Limited (Website: http://www.sprg.com.hk)
Shelly Cheng +852 2864 4857 shelly.cheng@sprg.com.hk
Yan Li +852 2114 4320 yan.li@sprg.com.hk
June Tuo +852 2864 4848 june.tuo@sprg.com.hk
Angela Shen +852 2864 4870 angela.shen@sprg.com.hk
Media: media@essex.com.cn
Investor Enquiry:
Investor Relations: investors@essex.com.cn
Topic: Press release summary
Source: Essex Bio-Technology Limited
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Essex Bio-Technology Limited |
| Mar 18, 2024 21:30 HKT/SGT |
|
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1% |
| Aug 16, 2023 19:06 HKT/SGT |
|
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22% |
| July 26, 2023 18:58 HKT/SGT |
|
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed |
| Apr 14, 2023 17:18 HKT/SGT |
|
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore |
| Mar 8, 2023 20:28 HKT/SGT |
|
Essex Bio-Technology Announces 2022 Annual Financial Results |
| Feb 22, 2023 18:48 HKT/SGT |
|
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration |
| Feb 10, 2023 21:06 HKT/SGT |
|
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases |
| Oct 13, 2022 22:40 HKT/SGT |
|
Essex Biotechnology Secures Exclusive Rights and Interests in SkQ1 for Ophthalmology from Mitotech |
| Aug 16, 2022 09:00 HKT/SGT |
|
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022" |
| Mar 22, 2022 20:12 HKT/SGT |
|
Essex Bio-Technology Announces 2021 Financial Results |
| More news >> |
 |
|
|
|
